1. Abbas, A.K., Haber S, and Rock, K.L. (1985) Antigen presentation by hapten-specific B lymphocytes, J. Immun. 135, 1661–1667.
2. Agren L, Lowenadler B, Lycke N. A novel concept in mucosal adjuvanticity: the CTA1DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin Al subunit. Immunol Cell Biol 1998, 76, 280.
3. Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 1998, 93, 2097–101.
4. Allison, A.C., Byars, N.E. (1991) Immunological adjuvants: Desirable properties and side-effects, Mol Immunol; 28, 279–284.
5. Aprile, M.A. and Wardlaw, A.C. (1966) Aluminum compounds as adjuvants for vaccines and toxoids in man: a review, Canadian Journal of Public Health
57, 343–360.